Researchers Identify Cancer-Suppressing Protein in Ovarian Cells
A new study reveals that the protein Calpain-5 functions as a tumor suppressor and offers a potential pathway for targeted therapy.
Updated on Oct. 26, 2026 in Cancer
Scientists have identified Calpain-5 (CAPN5) as a key tumor suppressor that is frequently downregulated in cases of epithelial ovarian cancer. Overexpressing this protein helps restrain the proliferation, invasion, and transition of cancer cells.
Why it matters
Understanding this regulatory mechanism reveals new vulnerabilities in ovarian cancer cells, specifically highlighting how patients with certain protein profiles may respond to targeted drug treatments.
The study demonstrates that CAPN5 catalyzes the cleavage of STIP1 at the R160 residue to trigger degradation. This process involves the K169 ubiquitination site, effectively suppressing the cancer progression pathways.
The players
Calpain-5
This protein functions as a tumor suppressor that is typically downregulated in epithelial ovarian cancer cells.
Pimitespib
This is a therapeutic drug that shows synergetic effects with Cisplatin in suppressing specific high-risk cancer cell profiles.
The details
CAPN5 works by inhibiting epithelial-to-mesenchymal transition and promoting apoptosis within cancer cells. When levels are low and STIP1 is high, researchers found that the drug Pimitespib can suppress cancer progression, particularly when used in combination with Cisplatin.
The Big Picture
This study extends our understanding of the Arg/N-degron pathway by identifying a specific protein-cleavage event that dictates cancer cell survival. By mapping these molecular interactions, the research bridges cellular degradation biology with therapeutic intervention strategies.
This research identifies a potential new biomarker and treatment strategy for patients with specific protein expression profiles in their ovarian cancer. It suggests that future testing could help doctors determine if combining Pimitespib with standard chemotherapy like Cisplatin would improve outcomes.
The takeaway
The discovery highlights how specific protein interactions can be exploited to stop the spread of cancer cells. It emphasizes the growing importance of personalized drug combinations based on a patient's unique molecular profile.
Further reading
For more information on the latest breakthroughs in oncology, visit our Cancer section.
More information
Read the complete academic research article for full methodological details.
Source note: This article includes information reported by Nature.
